Intralipid (Soya Oil, Purified)

Soybean oil in Intralipid is formulated as triglyceride droplets. After infusion, lipoprotein lipase hydrolyzes these droplets, releasing free fatty acids that are taken up by cells for energy production, membrane synthesis, and the provision of essential fatty acids such as linoleic and alpha‑linolenic acids, which the body cannot synthesize.

The dose of Intralipid is individualized by the prescribing clinician based on the patient’s caloric needs, weight, metabolic status, and laboratory parameters such as serum triglycerides. Dosing is calculated to achieve the desired percentage of total calories from lipids within a total parenteral nutrition regimen.

The safety of Intralipid in pregnancy and lactation has not been definitively established, and the product is classified as having an unknown pregnancy category. Use should be considered only if the potential benefit justifies any potential risk, and decisions are made by the treating physician in consultation with the patient.

To order Intralipid, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Intralipid is a soybean‑oil based emulsion, offering a balanced profile of omega‑6 and omega‑3 fatty acids. Compared with fish‑oil or olive‑oil emulsions, it provides a higher proportion of linoleic acid and is widely used for general parenteral nutrition. Choice of emulsion depends on patient‑specific factors such as inflammatory status, lipid tolerance and clinician preference.

Intralipid must be stored at 2‑8 °C (refrigerated). Keep the container in its original packaging, protect it from light, and avoid freezing or vigorous shaking, which can destabilize the emulsion. Once removed from refrigeration, the product should be used within the time frame specified by the manufacturer.

Intralipid is administered intravenously, typically as a continuous infusion added to a total parenteral nutrition bag or as a separate lipid infusion. The infusion rate is set by the clinician based on the prescribed lipid calories and is monitored closely for tolerance, serum triglyceride levels and any signs of adverse reactions.

Serious risks include fat overload syndrome, which can cause metabolic disturbances, and severe allergic reactions such as anaphylaxis. Rare but critical complications are pulmonary embolism from lipid particles and hepatic dysfunction manifested by elevated liver enzymes. Prompt recognition and management of these events are essential.

Intralipid is contraindicated in patients with known hypersensitivity to soy or egg phospholipids, those with severe hyperlipidaemia, and individuals with disorders of lipid metabolism that could predispose them to fat overload. It should also be used with caution in patients with severe hepatic impairment or uncontrolled sepsis.